BackSummary
Fiscal year marked by revenue growth from new business wins, but profitability constrained by investment costs and elevated operating expenses.
Full analysis
Revenue Growth Driven by Defense and Biomedical Wins
Margin Compression from Mix Shift and Cost Inflation
Cash Flow and Capital Allocation
Balance Sheet and Liquidity
Outlook and Strategic Direction